Pralifan

Pralifan Uses, Dosage, Side Effects, Food Interaction and all others data.

An anthracenedione-derived antineoplastic agent.

Pralifan has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.

Pralifan
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Pralifan
Availability	Prescription only
Generic	Mitoxantrone
Mitoxantrone Other Names	Mitoxantrona, Mitoxantrone, Mitoxantronum
Related Drugs	Gilenya, Tysabri, Vumerity, methotrexate, estradiol, Premarin, rituximab, Rituxan, cyclophosphamide, Xtandi
Type
Formula	C₂₂H₂₈N₄O₆
Weight	Average: 444.4809 Monoisotopic: 444.200884648
Protein binding	78%
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Spain
Last Updated:	September 19, 2023 at 7:00 am

Uses

Pralifan is a chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Pralifan is also used to associated treatment for these conditions: Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Lymphoma, Hodgkins, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma, Allogeneic peripheral haematopoietic stem cell transplant

How Pralifan works

Pralifan, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Pralifan also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

Toxicity

Severe leukopenia with infection.

Food Interaction

No interactions found.

Pralifan Drug Interaction

Moderate: diltiazem, diltiazemUnknown: sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprim, pancrelipase, pancrelipase, meperidine, meperidine, glucose, glucose, lithium, lithium, pregabalin, pregabalin, metoprolol, metoprolol, metoprolol, metoprolol, acetaminophen, acetaminophen

Pralifan Disease Interaction

Major: infections, heart disease, liver disease, myelosuppressionModerate: hyperuricemia

Volume of Distribution

1000 L/m2

Elimination Route

Poorly absorbed following oral administration

Half Life

75 hours

Clearance

21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]
28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]
16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]